Bayer Forms Endometriosis Collaboration with Evotec; Later Expanded to other Indications; BAY1817080 Discontinued
For the next five years, Bayer HealthCare Pharmaceuticals AG and drug discovery firm Evotec AG have agreed to identify three candidates against multiple targets--selected by both companies--for endometriosis.
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com